S&P 500 (SPY) $741.00 +1.65%Nasdaq 100 (QQQ) $724.08 +2.49%Dow Jones (DIA) $521.68 +0.76%Russell 2000 (IWM) $298.97 -0.29%Gold (GLD) $368.58 -1.35%10Y Bond (TLT) $87.45 +0.10% S&P 500 (SPY) $741.00 +1.65%Nasdaq 100 (QQQ) $724.08 +2.49%Dow Jones (DIA) $521.68 +0.76%Russell 2000 (IWM) $298.97 -0.29%Gold (GLD) $368.58 -1.35%10Y Bond (TLT) $87.45 +0.10%
Japan Market June 30, 2026 at 9:00 AM

Japan Morning Briefing: What to Watch on June 30, 2026

Tokyo investors face a cautiously optimistic open Tuesday as geopolitical tensions between the US and Iran show signs of easing, lifting global risk sentiment overnight. Wall Street’s broad-based rally, led by technology shares, sets a constructive backdrop for Japanese equities as the quarter draws to a close.

Wall Street Rally Fuels Risk Appetite

US markets closed sharply higher Monday, with the S&P 500 gaining 1.65% to $741.00 and the Nasdaq 100 surging 2.49% to $724.08. The Dow Jones added 0.76% to $517.75. Technology stocks led the advance as reports emerged that US and Iranian negotiators are heading to Doha for potential talks, reducing immediate conflict risks. The tech-heavy rally was further supported by continued AI-related corporate activity, including Salesforce’s ongoing acquisition spree in the artificial intelligence space.

Yen Weakness Boosts Export Outlook

The USD/JPY pair sits at ¥161.77, maintaining elevated levels that favor Japanese exporters. This currency backdrop should particularly benefit automotive giants like Toyota and technology exporters such as Sony, whose overseas earnings receive a significant boost from yen weakness. NISA investors holding these blue-chip export names may see continued momentum as the weak yen environment persists.

Key Themes for Tokyo Trading

Focus today centers on technology and export-oriented sectors, mirroring Wall Street’s tech leadership. Pharmaceutical stocks warrant attention following news that Eli Lilly and Regeneron were selected for an FDA initiative to accelerate manufacturing facility reviews—a development that could benefit Japanese pharma players like Takeda and Daiichi Sankyo. Quarter-end positioning may also drive volatility as institutional investors rebalance portfolios. With geopolitical risks temporarily subdued and the yen remaining export-friendly, Japanese equities appear well-positioned for a positive session, though investors should monitor any developments in US-Iran negotiations throughout the day.

This briefing is for informational purposes only and does not constitute investment advice. Please consult with a qualified financial advisor before making investment decisions.